Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells

Infect Immun. 2004 Jun;72(6):3684-7. doi: 10.1128/IAI.72.6.3684-3687.2004.

Abstract

Secretory leucoprotease inhibitor (SLPI) is an anti-inflammatory antiprotease which can inhibit lipopolysaccharide-induced NF-kappaB activation. We examined its ability to inhibit NF-kappaB activation induced by lipoteichoic acid and investigated the effects of oxidation or complex formation with neutrophil elastase on SLPI's anti-inflammatory properties in U937 myelomonocytic cells and macrophages.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Lipopolysaccharides / pharmacology
  • Macrophages / immunology
  • Membrane Glycoproteins / metabolism*
  • Monocytes / immunology*
  • NF-kappa B / metabolism
  • Oxidation-Reduction
  • Pancreatic Elastase / metabolism
  • Proteinase Inhibitory Proteins, Secretory
  • Proteins*
  • Receptors, Cell Surface / metabolism*
  • Receptors, Cell Surface / physiology*
  • Secretory Leukocyte Peptidase Inhibitor
  • Teichoic Acids / pharmacology
  • Toll-Like Receptor 2
  • Toll-Like Receptors
  • U937 Cells

Substances

  • Lipopolysaccharides
  • Membrane Glycoproteins
  • NF-kappa B
  • Proteinase Inhibitory Proteins, Secretory
  • Proteins
  • Receptors, Cell Surface
  • SLPI protein, human
  • Secretory Leukocyte Peptidase Inhibitor
  • TLR2 protein, human
  • Teichoic Acids
  • Toll-Like Receptor 2
  • Toll-Like Receptors
  • lipoteichoic acid
  • Pancreatic Elastase